Swedish Agency for Health Technology Assessment and Assessment of Social Services
Nuedexta for the treatment of pseudobulbar affect (in ALS patients)
Pseudobuldar affect is characterized by uncontrollable crying, laughter or other emotional displays. It can occur secondary to a neurological disorder or traumatic brain injury. The drug Nuedexta has been approved by the FDA in 2010 as a treatment option for pseudobulbar affect in patients with ALS or MS. However, in the EU Nuedexta has been deregistered since 2016 for market reasons according to the company. The question posed to the SBU Enquiry Service concerns what scientific studies that have documented the efficacy and safety of Nuedexta as a treatment of pseudobulbar affect in patients with ALS.
Share on Facebook
Share on LinkedIn
Share via Email
SBU does not issue recommendations or guidelines on how healthcare, dental care or social services should operate, or on which interventions and methods should be provided. SBU critically appraises and synthesises research on interventions and methods through systematic reviews.
Are there scientific studies on efficacy and safety of the drug Nuedexta (dextrometorphan/quinidine) for symptomatic treatment of pseudobulbar affect in patients with ALS?
Literature search
Project group
Nathalie Peira och Sally Saad at SBU.
